Connor, Clark & Lunn Investment Management (CC&L)’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.1M Sell
98,745
-2,421
-2% -$138K 0.02% 578
2025
Q4
$4.28M Buy
101,166
+52,549
+108% +$2.94M 0.01% 696
2025
Q3
$2.77M Buy
48,617
+27,282
+128% +$903K 0.01% 753
2025
Q2
$551K Sell
21,335
-3,219
-13% -$36.1K ﹤0.01% 1223
2025
Q1
$250K Sell
24,554
-24,171
-50% -$316K ﹤0.01% 1291
2024
Q4
$680K Buy
48,725
+5,336
+12% +$94.1K ﹤0.01% 1061
2024
Q3
$846K Buy
43,389
+2,306
+6% +$44K ﹤0.01% 934
2024
Q2
$764K Buy
41,083
+2,813
+7% +$59.3K ﹤0.01% 921
2024
Q1
$536K Buy
38,270
+5,155
+16% +$54K ﹤0.01% 1084
2023
Q4
$281K Buy
33,115
+317
+1% +$2.4K ﹤0.01% 1190
2023
Q3
$293K Sell
32,798
-9,513
-22% -$91.6K ﹤0.01% 1151
2023
Q2
$365K Buy
42,311
+12,429
+42% +$133K ﹤0.01% 1063
2023
Q1
$315K Buy
29,882
+19,127
+178% +$579K ﹤0.01% 1001
2022
Q4
$365K Buy
10,755
+10,041
+1,406% +$486K ﹤0.01% 946
2022
Q3
$34K Sell
714
-1,808
-72% -$108K ﹤0.01% 1072
2022
Q2
$144K Sell
2,522
-8,710
-78% -$550K ﹤0.01% 961
2022
Q1
$908K Buy
11,232
+7,692
+217% +$1.14M ﹤0.01% 681
2021
Q4
$717K Buy
+3,540
New +$768K ﹤0.01% 731
2021
Q3
Sell
-1,049
Closed -$270K 1163
2021
Q2
$270K Buy
+1,049
New +$290K ﹤0.01% 873
2020
Q1
Sell
-1,712
Closed -$554K 1119
2019
Q4
$554K Buy
+1,712
New +$496K ﹤0.01% 651
2014
Q2
Sell
-853
Closed -$171K 603
2014
Q1
$171K Sell
853
-2,274
-73% -$450K ﹤0.01% 632
2013
Q4
$566K Buy
3,127
+2,367
+311% +$382K ﹤0.01% 468
2013
Q3
$122K Buy
+760
New +$141K ﹤0.01% 477

Other funds holding NKTR